Algernon Pharmaceuticals Inc AGNPF

AGN significant upside

[Stockydoc]

This article from Medicalgold discusses AGN and why its improved fundamentals warrant a much higher valuation. Here's some details:

- AGN's strategy focuses on drug repurposing resulting in a lower risk of failure, reduced R&D costs, and a quicker time to market (6.5 yrs compared to 12-16 yrs)

- Discusses Ifenprodil which AGN is repurposing for idiopathic pulmonary fibrosis (IPF) and chronic cough

- Provides update on the phase 1 study for DMT in which researchers observed a statistically significant 40% increase in response to DMT treatment compared to control

- Lists upcoming catalysts including the pre-IND meeting for Phase 2b for Ifenprodil, attaining orphan drug designation for Ifenprodil, filing an application with the FDA for breakthrough therapy designation, and more

Looking at the technicals for AGN, shares were oversold in mid-July but have rebounded and could experience significant upside of 50-100% by the end of the year. AGN currently sits @ $4 (+10.50%) today.

https://www.medicalgold.ca/featured/algernon-human-clinical-trials-update

[TheBearInTheWoods]

"Author has purchased Algernon shares on the open market and may choose to buy or sell at any time without notice. Author has been compensated for marketing services by Algernon Pharmaceuticals Inc."